Interestingly, there was no difference in the expression of INF-γ pathway signatures, other T-cell-related genes (e.g., CD8A/B, PD-L1, and LAG3), and the genes that presumably modulate immune checkpoint sensitivity between responsive and non-responsive groups, suggesting that T-cell-suppressive inflammatory and mesenchymal phenotypes of tumor are associated with primary resistance to anti-PD-1 therapy. Here, CD8A is linked to neoplasm.